Study Title: Options for Delivering Isoniazid-Rifapentine (3HP) for TB Prevention (3HP Options Trial)
Study Setting/Site: The Makerere University Joint AIDS Program (MJAP), Mulago ISS Clinic in Kampala, Uganda
Overview:
This is a five-year project which started with a formative study in year one (November 2018)
Formative study objectives:
1. To assess the costs (direct and indirect) faced by clients to attend clinic visits
2. Conduct a pre-implementation assessment of 99DOTS using human-centered design (HCD) principles to refine the delivery strategy
3. To tailor and pilot test a preliminary decision aid focused on helping clients choose between receiving 3HP via DOT and SAT (via Knowledge, Attitudes and Practices, KAP, Interviews)
In partnership with the University of California San Francisco (UCSF), MJAP participated in the Test and Treat SEARCH Trial (NCT01864603) with PIs Moses Kamya and Diane Havlir.
a) In partnership with the University of California San Francisco (UCSF), MJAP participated in the Test and Treat SEARCH Trial (NCT01864603 with PIs Moses Kamya and Diane Havlir);
b) Client and Provider Perspectives of the Efficiency and Quality of Care in the Context of Rapid Scale-Up of Antiretroviral Therapy;
c) Successful Antiretroviral Therapy Delivery and Retention in Care Among Asymptomatic Individuals with High CD4+ T Cell Counts ≥350 cells/uL in Rural Uganda